--- title: "Natera (NTRA) stock listing, news and investor profile" url: "https://aibio.space/companies/natera/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Natera, Inc. (NASDAQ: NTRA), United States. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- NTRA Natera, Inc. NASDAQ · United States # Natera (NTRA) news Legal · 2026-08-07 ## [Natera appeals Guardant false advertising judgment after $292.5 million verdict](https://aibio.space/news/natera-appeals-guardant-false-advertising-judgment-after-292-5-million/) A jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit. ## Latest Natera news 1. 2025-12-05 Mergers [Natera closes Foresight Diagnostics acquisition, agrees to issue 1,127,982 shares](https://aibio.space/news/natera-closes-foresight-diagnostics-acquisition-agrees-issue-1-127-982/) Natera closed the deal on December 4, 2025. The press release describes an all-stock transaction with a $275 million upfront and $175 million in earnouts tied to milestones. ## Natera at a glance - **Ticker**: NTRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.09 billion ### Related companies - [Apimeds Pharmaceuticals US](https://aibio.space/companies/apimeds-pharmaceuticals-us/) AMEX: APUS - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) NASDAQ: CLDX - [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [Vaccinex](https://aibio.space/companies/vaccinex/) OTC: VCNX - [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) NASDAQ: FTH - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS ### Also on NASDAQ - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) SIGA - [Scinai Immunotherapeutics](https://aibio.space/companies/scinai-immunotherapeutics/) SCNI - [Cytek Biosciences](https://aibio.space/companies/cytek-biosciences/) CTKB - [SERA PROGNOSTICS, INC.](https://aibio.space/companies/sera-prognostics/) SERA - [SCYNEXIS](https://aibio.space/companies/scynexis/) SCYX - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) OGI ## What Natera does Natera is a diagnostics company that applies proprietary molecular and bioinformatics technology, centered on cell-free DNA, to disease management. It focuses on oncology, women's health and organ health. In oncology it sells Signatera, a personalized blood-based circulating tumor DNA test used to detect molecular residual disease and monitor recurrence. In women's health, its Panorama test is a noninvasive prenatal test that the company believes is the most accurate such test commercially available in the United States. In organ health it offers tests that measure donor-derived cell-free DNA to assess heart, lung and kidney transplant rejection. In December 2025 Natera acquired Foresight Diagnostics, adding ctDNA-based MRD tests and expanding into lymphoma. Revenues were $2,306.1 million in 2025, and the company processed approximately 3.5 million tests that year. Its Constellation cloud software lets laboratories run its algorithms locally, and it works with over 100 laboratory and distribution partners. | Product or program | What it is | Stage | |---|---|---| | Signatera | Personalized ctDNA test for molecular residual disease and recurrence monitoring | | | Panorama | Noninvasive prenatal test | | | Donor-derived cell-free DNA tests | Measure transplant rejection of heart, lung and kidney | | | Foresight MRD tests | ctDNA-based MRD tests using phased variants, acquired December 2025 | | | Constellation | Cloud software that lets laboratories run its algorithms locally | | Summarised from the company's [10-K filed Feb 27, 2026](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm). ## Natera annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$624.1 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | [$404.1 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | | Net income (loss) | [-$208.2 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | [-$190.4 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | | Cash from operations | [$215.3 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | [$135.7 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | | Cash and equivalents | [$1.08 billion](https://www.sec.gov/Archives/edgar/data/1604821/000162828026054525/) | [$945.6 million](https://www.sec.gov/Archives/edgar/data/1604821/000162828026054525/) | | Short-term investments | | [$22.7 million](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.09 billion. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Natera What is the ticker symbol of Natera? Natera, Inc. trades under the ticker NTRA on NASDAQ. Where is Natera listed? Natera, Inc. is listed on NASDAQ. Our directory also records these other listings: BCBA:NTRA; BCBA:NTRA.CI; BCBA:NTRAD; BIVA:NTRA; BMV:NTRA; DUS:45E; FWB:45E; GETTEX:45E; HAM:45E; HAN:45E; LS:A14VPJ; LSX:A14VPJ; MUN:45E; TRADEGATE:45E; XETR:45E. What is the SEC CIK of Natera? The SEC Central Index Key (CIK) for Natera, Inc. is 1604821. Its filings are on SEC EDGAR. How many shares does Natera have outstanding? 144,144,170 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Natera listed under? Our directory records Natera, Inc. under United States. What does Natera do? Our directory classifies Natera, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Natera? The ISIN recorded for Natera, Inc. is US6323071042. Does aibio.space cover Natera? aibio.space lists Natera, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Natera incorporated? SEC records list its state or country of incorporation as DE. What does Natera develop? Natera is a diagnostics company that applies proprietary molecular and bioinformatics technology, centered on cell-free DNA, to disease management. It focuses on oncology, women's health and organ health. What is Signatera from Natera? Signatera: Personalized ctDNA test for molecular residual disease and recurrence monitoring What is Panorama from Natera? Panorama: Noninvasive prenatal test Is Natera profitable? Natera, Inc. reported a net loss of $208.2 million for the fiscal year ended Dec 31, 2025, and generated $215.3 million of cash from operations, per its annual report to the SEC. How much does Natera spend on research and development? $624.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Natera have? $1.09 billion in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Natera Members talk about Natera (NTRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Natera, newest first. Each line links the filing it comes from. 1. 2026-02-27 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm) 2. 2025-12-05 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1604821/000110465925118664/tm2532406d4_ex99-1.htm) 3. 2025-02-28 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1604821/000155837025001869/ntra-20241231x10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NTRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-NTRA/). ## SEC filings and registration - **SEC name**: Natera, Inc. - **CIK**: 1604821 - **Industry (SIC)**: Services-Medical Laboratories (8071) - **US tickers**: NTRA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 13011 MCCALLEN PASS, AUSTIN, TX, 78753 - **Phone**: 650-249-9090 - **Shares outstanding**: 144,144,170 as of 2026-07-31 (10-Q filed 2026-08-07) - **Former names**: Natera, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1604821/000162828026054525/ntra-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/ntra-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1604821/000160482126000005/ntra-20260701.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1604821/000160482126000003/ntra-20260611.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1604821/000160482126000002/a20260605newdirectortomlyn.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1604821/000162828026032478/ntra-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1604821/000162828026032101/ntra-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1604821/000110465926047770/ntra-20260611xdef14a.htm) filed 2026-04-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001604821), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Natera, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NTRA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Natera, Inc. - **Ticker**: NTRA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US6323071042 - **Other listed symbols**: BCBA:NTRA; BCBA:NTRA.CI; BCBA:NTRAD; BIVA:NTRA; BMV:NTRA; DUS:45E; FWB:45E; GETTEX:45E; HAM:45E; HAN:45E; LS:A14VPJ; LSX:A14VPJ; MUN:45E; TRADEGATE:45E; XETR:45E - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NTRA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/natera/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Natera (NTRA) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/natera/